Group items tagged

Weed Oil For Sale Have you been in search of cannabis oil for sale ? In need of thc oil for sale ? Medical Marijuana Buds is your answer. Cannabis oil is one of the most unusual oil amongst the oil range, simply because of the plant from which it is gotten from. Although cannabis and hemp have been used over the years as a natural growing herb, its awareness as a drug in certain parts of the world have strained the relationship between it's users on one hand and legal authorities on the other hand . Not withstanding, Cannabis essential oil is a very useful oil, and is widely regarded as one of the most effective oils for dealing with certain illnesses. Cannabis essential oil is gotten steam distilling the flowers and upper leaves of cannabis plants using steam. THC Oil For Sale Online and enjoy these Benefits: - Anxiety and Stress - Appetite Booster - Pain Reliever - Cancer Prevention - Heart Health - Skin Protection - Glaucoma - Headaches and Migraines Despite the fact that this list clearly shows that cannabis essential oil can effectively be used to cure most of our common health conditions, it still doesn't cancel the fact that it is a potent chemical substance extracted from a plant with psychotropic substances. As such, great care should be taken on its use with respect to the quantity and conditions under which it is being used. It is adviceable to always consult a professional about mixing essential oils and present medications before adding any new elements into your health regime. Medical cannabis oil for sale We do have medical cannabis oil for sale at our online shop which is cheap and affordable for all our customers. Our Cannabis are of great Quality and our standards are incomparable. Purchase from us and get the best for less. Note: If you are looking to buy Cannabis Oil online, hash oil for sale, Medical Marijuana Buds is the right place for you. Feel free to contact our customer service or live help assistance for wha

The All-Party Parliamentary Group (APPG) on Pharmacy published a new report on Monday (January 23) that calls for "urgent action" to relieve funding pressure so there are "opportunities" for community pharmacy teams to deliver even more for their patients. The report highlights the need for a new "strategic vision" for pharmacy and highlights opportunities for the network to be empowered to deliver even more for patients. However, the manifesto also underlines that there are the very real risks that this opportunity may be lost if significant and ongoing pressures are not addressed. The recommendations are based on written and oral evidence gathered from frontline pharmacists, GPs, professional bodies and healthcare experts. To harness the potential of pharmacy, the report recommends the Government must take urgent action to relieve the funding pressures on the community pharmacy sector in the short term and review the long-term funding model for pharmacy. It also suggested the Government must harness the power of pharmacy to help the NHS deal with the COVID-19 backlog and the UK's growing healthcare challenges. It further recommended that future commissioning and funding must recognise that community pharmacy is the front door to the NHS for many patients.

A total of 525 candidates have passed the common registration assessment for pharmacists held in November, the regulators GPhC and PSNI have announced on Tuesday. With 937 candidates sitting for the registration assessment, held jointly by the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of Northern Ireland (PSNI) on 3 November, the pass rate was 56 per cent, down from the 61 per cent for the Autumn 2021. Among the GPhC candidates, 59 per cent were sitting for the first time, 30 per cent for the second time and 8 per cent for the third time. (The break-up was not available for the 3 per cent PSNI candidates.) In comparison, for the June sitting 89 per cent of candidates were sitting for the first time, 7 per cent were sitting for the second time and 4 per cent were sitting for the third time. "We would like to congratulate the successful candidates and we look forward to them joining our register and continuing to the next stage of their career," Duncan Rudkin, GPhC chief executive said.

Microplates are an important part of many laboratory experiments. They are often used to measure the results of a process or to test a product. When working with microplates, it is important to use the right closure and sealing method to ensure accurate results. This article will discuss the different types of closures and seals available, as well as how to choose the right one for your needs. HEAT SEALING METHOD One of the most common methods for sealing microplates is the heat seal method. This method uses a heating element to melt the top layer of the plate, which then bonds to the bottom layer. Heat sealing is a quick and easy way to seal a microplate, and it is often used for plates that will be stored for long periods. For this reason, heat sealing is the preferred method for sealing storage plates. Heat sealing is also one of the most cost-effective methods for sealing microplates. If you are interested to learn more about heat sealing, you may be surprised to find that there are many pieces of heat sealing equipment for sale at a very reasonable price. You just need to take the time to find the right one for your needs. As much as possible, choose the one with adjustable temperature settings so you can find the perfect heat for your microplates. More often than not, 225 degrees Fahrenheit is the ideal temperature for heat sealing.

It is important to revisit our financial situation early in the tax year and the various ways in which we could save some tax, extract cash from the business and reduce tax liabilities. We list below some of the tax planning opportunities available in the current tax year (05 April 2023 for individuals and 31 March 2023 for corporates). Salaries As a director of a limited company, you are entitled to be paid a salary for your work and so are members of your family who work for the company. Paying at least a small salary can be very beneficial, particularly when the recipient does not already have the 35 qualifying years needed for entitlement to the full single-tier state pension, which is payable to those who reach state pension age on or after 06 April 2016. To preserve entitlement to state pension, and to ensure the year counts as a qualifying year, it is advisable to pay a salary at least equal to the lower earnings limit for National Insurance Contributions (NIC) which is set at £578 per month for 2022/2023 i.e., £9,100 per annum. Salaries may be beneficial where funds are needed in a recession for example, and the company does not have sufficient reserves to pay dividends. Dividends The annual tax-free dividend allowance for 2022/2023 is £2,000. Although referred to as an "allowance", it is actually a zero-rate band and therefore uses up your basic or higher rate band as appropriate. Dividends are treated as the top slice of income and for 2022/2023, dividend income is taxed at 8.75% to the extent it falls within the basic rate band, 33.75% if it falls within the higher rate band and 39.35% to the extent it falls within the additional rate band.

The Pharmaceutical Services Negotiating Committee (PSNC) has published a guidance for community pharmacies to help them in the implementation of the new Prescription Prepayment Certificate (PPC) for hormone replacement therapy (HRT). The new policy will rollout from 1 April 2023, patients who are not already exempt from NHS prescription charges will be able to purchase an annual HRT PPC for the cost of two single prescription charges Major concern raised by PSNC is that the NHS systems have not kept pace with policy, as the certificate is launching without the IT in place to support it. PSNC has been clear that this is totally unacceptable, including raising this with Ministers directly and warning them that introducing the PPC without this infrastructure risks causing confusion for some patients and adding to the burden for pharmacy teams. "Government recognises the challenges but is determined to move forwards with the policy, said the committee. "DHSC has recognised the impact this will have on pharmacies and we are still pressing for appropriate financial compensation. We have also sought guidance for GPs, and now published our own guidance to try to make the launch go as smoothly as it can for pharmacy teams."

Sensodyne, the No.1 dentist recommended toothpaste brand for sensitive teeth is relaunching its Sensitivity & Gum range with an improved formula and revitalised packaging. Available in two variants - Mint and Whitening - the range's dual action formula is clinically proven to protect sensitive teeth and improve gum health. Based on a sample survey from across the GB, of those that suffer from gum conditions, 71% claim to also have sensitive teeth[1]. Figures in 2022 showed that 90% of dental practices were unable to take on new adult NHS patients[2], making it challenging for adults to get support or advice from their dentist on these concerns. This shows a clear market need for a multi-purpose product which offers dual action to for sensitive teeth and gum problems. The relaunched Sensitivity & Gum range features a new Micro Foam formula which targets and removes plaque bacteria. With twice daily brushing, the formulation reaches the areas in between the teeth and along the gumline. It also builds a protective layer over sensitive areas of the teeth for daily repair, and the mint flavour gives a soothing sensation. For consumers looking for whitening benefits, the Sensitivity & Gum Whitening formulation not only helps protect sensitive teeth but helps to remove stains for whiter looking teeth resulting in a healthy and confident smile.

Department of Health and Social Care (DHSC) has increased the rate of discount deduction for generics from 17.52 per cent to 20 per cent. The Drug Tariff for April 2023 will contain changes to the discount deduction arrangements for pharmacy contractors, which will include- all concession lines to be considered as Group Items for Discount Not Deducted i.e. DND or zero discount (ZD) items; and rate of discount deduction for generics to increase from 17.52% to 20% The Pharmaceutical Services Negotiating Committee (PSNC) and DHSC agreed on the changes for all concession lines to be considered as Group Items for Discount Not Deducted. Therefore from 1 April 2023, a new category will be introduced into Part II of the Drug Tariff 'Drugs for which discount is not deducted'. However, the committee had rejected the changes in the rate of discount deduction for generics. It said, "Following pressure from NHS England, Ministers have now chosen to impose changes to the previously agreed discount deduction arrangements, which come into effect from 1 April, and will be kept under review."

To help the pharmacists understand the Serious Shortage Protocols (SSPs) for three Hormone Replacement Therapy (HRT) products that was recently announced by the Department of Health and Social Care (DHSC)'s, the Pharmaceutical Services Negotiating Committee has shared top tips on the correct SSP endorsement and submission requirements. Top Tips by PSNC for pharmacists on HRT SSPs: Always double check that endorsements reflect the requirements outlined in the supporting guidance published for each SSP on the dedicated page of the NHSBSA's website. When endorsing using EPS, contractors are reminded to select the SSP endorsement and input the correct three-digit reference number leaving a space in between 'SSP' and the three-digit reference number for example, SSP 019. Remember to insert the leading zero in the three digit reference number. Each of the affected HRT medicines has its own SSP reference number. Check that the correct SSP number is endorsed for e.g. for Oestrogel® Pump-Pack 0.06% gel the SSP endorsement should be 'SSP 019'. Please note the 'NCSO' endorsement is no longer accepted for SSPs. Endorse the SSP product dispensed including the quantity. Ensure your endorsements are accurate and clear - NHSBSA processing staff must be able to determine what has been supplied. Contractors should note that SSP claims submitted using EPS tokens are no longer permitted.

Any prescription for Promethazine hydrochloride 10mg tablets x 56 submitted for payment to the NHSBSA for July 2022 will be reimbursed at the new price of £17.77 not as per the price concession of £13.45 announced in the 4th concessions update published on 29 July 2022, said the Pharmaceutical Services Negotiating Committee (PSNC). In July 2022, PSNC received several reports from contractors unable to obtain Promethazine hydrochloride 10mg tablets (56) at the published Drug Tariff price of £4.24. Therefore, it submitted a request for a price concession, which was granted and subsequently published but this was later withdrawn after confirmation from the Department of Health and Social Care (DHSC) that due to the price change mechanism, the reimbursement price for Promethazine hydrochloride 10mg tablets has increased from £4.24 to £17.77 for July 2022. PSNC said, "Following the price change mechanism rules, for generic drugs (excluding drugs in Category M), a price change up to and including the 8th of the month takes effect for prescriptions dispensed in that same month. Any price change after the 8th takes place in the following month."

The Community Pharmacist Consultation Service (CPCS) will be expanded to enable urgent and emergency care settings to refer patients to a community pharmacist for a consultation for minor illness or urgent medicine supply from Monday (15 May), the DHSC and NHSE said. The service builds on the progress made in GP referrals via the CPCS and hospital referrals under the Discharge Medicine Service. It was originally planned to launch in March, and fee for this service will be the existing CPCS fee of £14, as per the agreement for both year 4 and year 5 of the Community Pharmacy Contractual Framework (CPCF) 2019 to 2024 5-year deal. In an update on the CPCF, published today (12 May), the Department of Health and Social Care (DHSC) and NHS England (NHSE) has also committed to the 4 October 2023 launch date for the Tier 2 of the Pharmacy Contraception Service, subject to a positive evaluation of the pilot. The Tier 1 of the service was launched on 24 April, delayed by over three months. This new service enables community pharmacists to provide ongoing management, via a patient group direction (PGD), of routine oral contraception that was initiated in general practice or by a sexual health clinic. The fees for this service are as follows: a fee for each consultation of £18; and a set-up fee of £900, paid in instalments. The Tier 2 will "enable community pharmacists to also initiate oral contraception, via a PGD, and provide ongoing clinical checks and annual reviews," Alette Addison, deputy director for pharmacy, dental and optical at the DHSC and Ali Sparke, director for dentistry, community pharmacy and optometry at the NHSE, said in a letter.

Boots and the Pharmacists' Defence Association (PDA) Union have released a joint statement to confirm that there will be a pay increase for trainee pharmacists in England and Northern Ireland from April 2024. From 1 April 2024, the new hourly pay rate for trainee pharmacists working at Boots pharmacies will be £12.69 for Zone A in England/Northern Ireland, £13.79 for Zone B in England and £14.05 for Zone C in England. "This increase will be applied centrally in the April pay run," said the statement from the Boots and the PDA Union. Team members can see the new rate of pay in the Benefits Box during the annual enrolment window from 20 February 2024, it added. In August 2023, pay for trainee pharmacists at Boots in England and Northern Ireland was increased to £11.64 per hour for Zone A, £12.77 per hour for Zone B and £12.88 per hour for Zone C.

Pharmacy chain Superdrug has introduced what it asserts to be the most affordable private flu vaccinations offered on the UK high street. The vaccinations will be priced at £8.79 for 17.2 million members of its Ghada , and £16.99 for non-members. The 2023-24 vaccination service is set to become available across 150 of its stores starting from early September. Superdrug has taken this step in response to a change in NHS England's inclusion criteria, which has rendered the 12 million individuals aged 50-65 ineligible for the NHS flu vaccination service, the company said. The company is anticipating heightened demand for private flu vaccinations due to the postponed commencement of the NHS service and alterations in eligibility for free flu jabs. "Our waiting list for private flu vaccination services has already exceeded last year's figures, indicating a heightened demand this year," said Ghada Beal, Superdrug's Healthcare Director. "Providing this service at a more accessible price-point is significant, given the eligibility changes that will impact millions. Our private flu vaccination services provide a convenient means for individuals to safeguard themselves against flu and its potential complications." In May, the government's annual flu vaccination programme letter indicated that individuals aged 50 to 64 won't receive free flu vaccinations in the 2023/24 season. Moreover, the NHS plans to delay flu vaccine distribution to October, with the goal of enhancing protection for those aged 65 and older and other eligible groups during the winter months.

Boots UK is set to start recruiting for a new superintendent pharmacist as Marc Donovan moved into a new role. The company announced the appointment of Anne Higgins as the new pharmacy director for Boots UK. A Boots veteran for 25 years, she has been in the role of director for stores for more than two years since starting her journey as a pre-register pharmacist in July 1997. Marc Donovan will be moving into the new role of director of healthcare development and public affairs for Boots. Earlier this year Donovan was appointed the Order of the British Empire (OBE) "for services to pharmacy" in the Queen's Birthday Honours list. Donovan and Higgins will be reporting to Jamie Kerruish, the director of healthcare at Boots UK. A Boots spokesperson told Pharmacy Business: "We will be recruiting for a new superintendent pharmacist and once this appointment is made, Marc will hand over his superintendent responsibilities"

If you're looking for the best probiotic brands, you've come to the right place. In this blog post, we will discuss how to find the right probiotic brands for your needs. We'll go over factors such as price, quality, and customer reviews to help you make an informed decision. We will also discuss the different types of probiotics and how to select the right one for you. So whether you're just starting out on your probiotic journey or you're looking for a new brand to try, read on for our top tips! HOW TO CHOOSE A PROBIOTIC BRAND? When choosing a probiotic brand, it's important to consider factors such as price, quality, and customer feedback. Price is often the first factor people consider when selecting a probiotic brand. However, it's important to remember that cheaper is not always better. Quality should be your main priority - some brands may be more expensive but offer superior probiotic strains with higher concentrations of beneficial bacteria compared to others. A probiotic should contain at least 10 Billion CFUs (colony-forming units) to be considered effective. The ingredients it should have are lactic acid bacteria, bifidobacteria, and Enterococcus. So , these probiotics are good for gut health and digestion. In addition, they should consist of bacterial strains that are resistant to stomach acid and bile, as these can break down beneficial bacteria before they reach the gut.

The Royal Pharmaceutical Society (RPS) has appointed Laura Wilson as Director for Scotland commencing 23rd January 2023. Laura, is currently Policy and Practice Lead for RPS in Scotland. She is accountable for bringing national RPS policy to life for members in Scotland, while contributing to the GB wide professional leadership agenda. She will work closely with the Scottish Pharmacy Board, senior NHS officials and other key stakeholders across the breadth of the pharmacy profession and beyond to ensure pharmacy is on the forefront of healthcare in Scotland. She joins the existing team of RPS Country Directors, which includes Elen Jones, Director for Wales and James Davies, Director for England and will report directly to the Chief Executive. Laura Wilson said: "I am delighted to be appointed Director for Scotland having worked as part of the RPS Scotland team as the policy and practice lead. It will be an honour to continue the fantastic work started by former Director Clare Morrison to bring Pharmacy 2030, our vision for pharmacy in Scotland in the future, to life and supporting pharmacy teams to deliver person centred care.

As part of a new blueprint for primary care, the government today (May 9) announced an investment of £645 million over two years to expand community pharmacy services in England. In a statement, NHS England said: "For the first time ever, patients who need prescription medication will be able to get it directly from a pharmacy, without a GP appointment, for seven common conditions including earache, sore throat, or urinary tract infections." Prime minister Rishi Sunak hopes that the measures will help end the "all-too stressful wait on the end of the phone for patients" by freeing up 15 million slots at doctors' surgeries over the next two years. "We will end the 8am rush and expand the services offered by pharmacies, meaning patients can get their medication quickly and easily," he said Almost half a million women will no longer need to speak to a practice nurse or GP to access oral contraception and will instead be able to pop into their local pharmacy for it, according to the government announcement. Blood checks for people suffering from moderate risk of heart attack or stroke conducted in community pharmacies will more than double from 900,000 last year to 2.5 million next year. NHS chief executive Amanda Pritchard said the "ambitious package" would help transform how care is provided within the health service "with pharmacies playing a central role in managing the nation's health including providing lifesaving checks and medication for common conditions for the first time.

Labour MP Barry Gardiner has raised concerns that the £645 million cash injection announced by the government for community pharmacy is, in effect, 'frozen funding' for the next two years. Speaking on Tuesday (May 9) on the BBC's Politics Live, Gardiner said funding for community pharmacies "was cut before 2015, then it was frozen and now the latest announcement says that it's going to be frozen for a further two years." He said with a current national contract, which already represented a 25 per cent funding cut in real terms, it was not appropriate to ask for community pharmacy "to take on more work" without adequate support. "I heard the prime minister earlier this morning (May 9) on TV saying 'we are investing more in pharmacies'. "No you are not. You just concluded a contract that says for the next two years it will be absolutely flatlined." He added that "there will be no more money" for community pharmacy and that steeply rising costs due to inflation were "eating into that contract's health". Gardiner said community pharmacists "do a phenomenal job" but regretted that from a total of just 11,000, some 700 pharmacies have been lost due to funding cuts.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

We all know that clothes can make us look and feel good. But did you know that they can also be used to relieve some common health issues? That's right - by choosing the right fabrics and materials, you can help alleviate conditions like skin irritations, back pain, and even headaches. So the next time you're feeling under the weather, reach for your wardrobe first - it just might hold the key to feeling better. COMPRESSION SOCKS FOR DIABETES Compression socks for diabetes have become an invaluable tool for people with diabetes to keep their lower legs healthy. Wearing compression socks can help increase circulation in diabetic patients, which is incredibly important for the health of their feet and ankles. Additionally, if the patient suffers from swelling or poor blood circulation - compression socks can help reduce those negative side effects. As a result of wearing these specialty socks, many diabetics are kept more comfortable and experience less fatigue in their legs throughout the day. With many different sizes and varieties available - it's easy for anyone suffering from diabetes to find the perfect pair of compression socks to suit their specific needs and lifestyle. There are various diabetic stockings designed for men and women. Take the time to find the right pair for you.